Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL26P34 (ribosomal protein L26 pseudogene 34) is a processed pseudogene in the human genome related to the ribosomal protein L26 gene (RPL26). Processed pseudogenes are nonfunctional segments of DNA that originate from retrotransposed mRNA and are generally unable to produce functional protein products. RPL26P34 has high sequence similarity to its parent gene RPL26, which encodes a component of the 60S ribosomal subunit essential for protein synthesis, but RPL26P34 itself lacks protein-coding ability due to loss of regulatory elements or disruptive mutations typical to pseudogenes[1][2][5][7][10][8][11]. There is no evidence of RPL26P34 being involved in signaling, enzymatic activity, transport, transcription regulation, or disease, nor does it have any known interactions with drugs or function as a biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L26 pseudogene 34 (RPL26P34).